Supplemental Table 1. Full titles of 74 lung cancer clinical trials included in the analysis

Protocol Number / Protocol Title
CALGB 39802 / Video-Assisted Lobectomy for Peripheral (≤ 3 cm), N0, Non-Small Cell Lung Cancer: A Phase II Feasibility Study
CALGB 9334 / Sclerosis of Pleural Effusion By Talc Thoracoscopy Versus Talc Slury: Phase III Clinical Study
CALGB 9335 / Video Assisted Wedge Resection (VAR) and Radiotherapy for High Risk T1 Non-small Cell Lung Cancer: Phase II Study
CALGB 9732 / A Randomized Phase III Study Comparing Etoposide and Cisplatin with Etoposide, Cisplatin and Paclitaxel with Extensive Small Cell Lung Cancer
CALGB30610 / Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin Or Carboplatin And Etoposide
E1500 / A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy
E1501 / A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND# 65,056) in Patients with Advanced Non-Small Cell Lung Cancer
E1503 / A Phase II Trial of Triapine (NSC #663249) in Combination with Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
E1504 / Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma
E1505 / A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
E1508 / A Randomized Phase II Study of Cisplatin and Etoposide In Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer
E1512 / A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
E1584 / Immunohistochemical Analysis of the Lung
E1588 / Phase II - III Study of Chemotherapy of Extensive Small Cell Carcinoma of the Lung
E1592 / Phase II Study of Topotecan in Patients with Extensive Small Cell Lung Cancer
E1594 / A Randomized Phase III Trial in Metastatic Nonsmall Cell Lung Cancer
E1597 / A Phase II Trial of Gemcitabine in Refractory or Relapsed Small Cell Lung Cancer
E1599 / A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemcitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients
E1C93 / Phase II Study of VIP (Etoposide, Ifosfamide and Cisplatin) in Treatment of Invasive Thymoma
E1C97 / Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma
E1C99 / Phase II Study of Carboplatin plus Paclitaxel Treatment of Advanced Thymoma or Thymic Carcinoma
E2501 / A Double Blind Phase II Study of BAY 43-9006 in Patients with Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
E2508 / Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients with (Bevacizumab-eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
E2511 / Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
E2512 / A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-amplified Squamous Non-Small Cell Lung Cancer
E2588 / Phase II Protocol for Chemotherapy in Metastatic Non-small Cell Bronchogenic Carcinoma Gallium Nitrate, Amonafide, Teniposide
E2590 / Biomarkers in Small Cell Lung Cancer
E2591 / Phase III Study Comparing Combination Chemotherapy and Radiation Therapy with Preoperative Chemotherapy and Surgical Resection in Patients with Non-Small Cell Lung Cancer with Spread to Mediastinal Lympth Nodes
E2593 / Phase II Study of Chemotherapy Plus All-Trans-Retinoic Acid in Patients With Extensive Stage Small Cell Lung Carcinoma
E2595 / Taxotere For Malignant Mesothelioma:A Phase II Study of The Eastern Cooperative Oncology Group ®
E2596 / A Phase II Study of Paclitaxel plus Etoposide plus Cisplatin (PET) and Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer
E2597 / A Phase III Trial of Induction Paclitaxel and Carboplatin followed by Standard Radiotherapy (64 Gy/7 weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 eeks) for Patients with Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer
E2598 / Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/neu (+) Advanced NSCLC
E3501 / A Phase II Study of Cisplatin plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer
E3503 / A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to OSI-774 (Erlotinib) in the First-line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
E3508 / A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer
E3588 / Phase III Study of Cisplatin plus Etoposide Comiuned with Standard Fractionated Thoracic Radiotherapy versus Cisplatin plus Etoposide Combined with Multiple Daily Fractionated Thoracic Radiotherapy for Limited Stage Non Small Cell Lung Cancer
E3590 / Prospective Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II and Stage IIIa Non-Small Cell Lung Cancer: Intergroup
E3592 / Cisplatin Plus Etoposide Versus Daily Oral Etoposide in Elderly Patients with Extensive End Stage Small Cell Lung Cancer: A Phase III Trial of the Eastern Cooperative Oncology Group
E3598 / A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients with Stage III NSCLC
E4503 / Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer
E4508 / Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy
E4512 / A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
E4592 / Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer
E4593 / Phase II Study of Hyperfractionated Accelerated Radiation Therapy for Advanced, Unresectable Non-Small Cell Lung Cancer
E4599 / Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC
E5501 / A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced with Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide
E5508 / Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
E5585 / A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Carcinoma to Combination Chemotherapy
E5592 / Phase III Trial Comparing Etoposide/Cisplatin versus Etoposide/Cisplatin/G-CSF versus Taxol/Cisplatin in Advanced Non Small Cell Lung Cancer
E6501 / Interferon Alpha (NSC# 377 523) Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC)
E6508 / A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
E6597 / Phase I Pilot Trial of Adenovirus p53 in Bronchioloalveolar Cell Lung Carcinoma (BAC) Administered by Bronchoalveolar Lavage
E7593 / A Randomized Comparison of Topotecan Versus Observation Following Treatment with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer: A Phase III ECOG Trial
E8592 / A Prospective Randomized Trial of Bleomycin vs. Doxycycline vs. Talc for the Intrapleural Treatment of Malignant Pleural Effusions
E8597 / Phase I Pilot Trial of Adenovirus p53 and Radiotherapy on Nonsmall Cell Lung Cancer
EA5123 / Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC
EA5142 / Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NonSmall Cell Lung Cancers
ECOG91025 / Phase III Double-Blinded Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors in Stage I Non-Small Cell Lung Cancers
EST1588 / Phase II-III Study of Chemotherapy of Extensive Disease Small Cell Carcinoma of the Lung
EST1589 / Phase II Protocol for Chemotherapy in Metastatic Non-Small Cell Bronchogenic Carcinoma
EST1590 / Phase II Study of Taxol in Patients with Extensive
NCCTGE1B03 / Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial
PA586 / Pilot Study with Weekly Chemotherapy for Patients with Extensive Small Cell Lung Cancer
PC589 / Ifosfomide, Carboplatin and Etoposide (ICE) Chemotherapy for Extensive Stage Small Cell Lung Cancer
PY586 / Phase II Study of Combined Recombinant Beta and Gamma Interferon in Metastatic Non-Small Cell Lung Cancer
RTOG 9309 / A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy, and Concurrent Chemotherapy plus Radiotherapy followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer
RTOG0212 / A Phase II/III Randomized Trial of Two Doses (Phase III--Standard vs High) and Two High Dose Schedules (Phase II—Once vs Twice Daily) for Delivering ProphylacaticCranidal Irradiation for Patients with Limited Disease Small Cell Lung Cancer
RTOG0214 / A Phase Iii Comparison Of Prophylactic Cranial Irradiation Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
RTOG0617 / A Randomized Phase III Comparison Of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy With Concurrent And Consolidation Carboplatin/Paclitaxel +/- Cetuximab (Ind #103444) In Patients With Stage Iiia/Iiib Non-Small Cell Lung Cancer
RTOG0937 / Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)
S9416 / Induction chemoradiotherapy followed by surgical resection of NSCLC involving the superior sulcus (Pancoast Tumor): A phase II trial.
S9990 / A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) And Selected IIIA (T3N1) Non-small Cell Lung Carcinoma (NSCLC)
SO220 / A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)

CALGB, Cancer and Leukemia Group B; E designates Eastern Cooperative Oncology Group (ECOG); RTOG, Radiation Therapy Oncology Group; S designates Southwest Oncology Group (SWOG)